









Markets
/
Stocks
/
nasdaq-pstv
/

Plus Therapeutics Inc

PSTV

View Detailed Chart

0.585USD

+0.102+21.12%

Market hours （ET）Quotes delayed by 15 min

9.94MMarket Cap

LossP/E TTM



Plus Therapeutics Inc

0.585

+0.102+21.12%

Overview Company Financials

Financials

Intraday

30m

Today

+21.12%

5 Days

+10.42%

1 Month

+97.37%

6 Months

-52.88%

Year to Date

-49.13%

1 Year

-66.18%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

9.167

Target Price

1466.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Plus Therapeutics Inc

PSTV

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(3)

Buy(9)

Indicators

Sell(0)

Neutral(3)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.028

Buy

RSI(14)

63.260

Neutral

STOCH(KDJ)(9,3,3)

52.193

Neutral

ATR(14)

0.080

High Vlolatility

CCI(14)

69.843

Neutral

Williams %R

31.189

Buy

TRIX(12,20)

2.469

Buy

StochRSI(14)

66.540

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.527

Buy

MA10

0.506

Buy

MA20

0.424

Buy

MA50

0.353

Buy

MA100

0.578

Buy

MA200

0.894

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Ticker SymbolPSTV

CompanyPlus Therapeutics Inc

CEODr. Marc H. Hedrick, M.D.

Websitehttp://www.plustherapeutics.com/